May 17, 2020

Startup WellTrackONE secures $1.5 million to improve Medicare wellness tests

Admin
2 min
Startup WellTrackONE secures $1.5 million to improve Medicare wellness tests.jpg
Underneath Obamacares new stipulations, primary care providers are required to conduct wellness exams for their Medicare patients. With this in mind, W...

Underneath Obamacare’s new stipulations, primary care providers are required to conduct wellness exams for their Medicare patients. With this in mind, WellTrackONE, the South-Carolina based healthcare startup, raised over 1.5 million from Easton Capital in order to better serve its patients with accessible and affordable testing options.

These wellness exams contain the standard details about patients’ health: height, weight, blood pressure and a brief overview of medical and family history. Neurological tests are also done, to ensure that patients are appropriately receiving preventative care as well as ongoing care for mental ailments like depression, Alzheimer’s or Dementia.

In an emailed response to questions, CEO Peter Bechtel said that so far, it is finding the most traction with accountable care organizations and integrated delivery networks.

“That has taken off like a rocket. What we bring to them is compelling: more revenue for their doctors, a method to significantly reduce healthcare cost by avoidance of catastrophic illness and injury, increase in ACO attribution, minable data for outcomes and clinical measures.”

He added that the startup expects to expand its staff from 19 to more than 50 by the end of the year.

Although the platform’s goal is to have 1,000 primary-care physicians on board, the organization is embracing accountable care organizations as a critical source of business. This new platform will handle patient outreach, evaluation and scheduling capabilities across a range of healthcare practices from primary-care practices to large healthcare organizations. Now, not only will patients have better access to their own healthcare information, but physicians will be able to do a better job of tracking their patients.

Along with its partners, myCatalyst works alongside WellTrackONE in order to enable an ACO to capture annual wellness visits and checkup data and integrate all of the findings into one health information exchange.

 

Share article

Jun 23, 2021

Introducing Dosis - the AI powered dosing platform

AI
medication
personalisedmedicine
chronicdisease
3 min
Dosis is an AI-powered personalised medication dosing platform that's on a mission to transform chronic disease management

Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works. 

When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing. 

The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced. 

What is the Strategic Anemia Advisor? 
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease. 

SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool. 

What else is Dosis working on? 
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs. 

What are Dosis' strategic goals for the next 2-3 years? 
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.

What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.

Share article